🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Familial Hypercholesterolemia

Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) NCT07447648n/a13 sites📍 Paris📍 Caserta📍 Catania Fondazione SISA (Societa Italiana per lo Studio della Arter… The ORIGIN-FH Study NCT07470723NA1 site📍 Madison University of Wisconsin, Madison · Tests: Screening for FH Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) NCT06960902NA9 sites📍 Dijon📍 Lille📍 Lyon Nantes University Hospital · Tests: Coronary CT scan with CAC score measurement Child-Parent Familial Hypercholesterolemia Screening NCT04529967n/a6 sites📍 Hefei📍 Qidong📍 Shanghai Children's Hospital of Fudan University · Tests: no interventions Multicomponent Intervention Study- Blood Donors With High Cholesterol NCT05693701NA1 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Implementation Strategy Bundle, Usual care notification A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia NCT06568471Phase 318 sites📍 Beijing📍 Beijing📍 Beijing Hasten Biopharmaceutical Co., Ltd. · Tests: Lerodalcibep, matching placebo Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia NCT07591298Phase 21 site📍 Changsha CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Tests: SYH2070 injection dose1, SYH2070 injection dose2 Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia NCT06597019Phase 366 sites📍 San Francisco📍 San Francisco📍 Washington D.C. Novartis Pharmaceuticals · Tests: Inclisiran, Placebo 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH) NCT04941599Phase 21 site📍 Nashville Vanderbilt University Medical Center · Tests: 2-Hydroxybenzylamine, Placebo A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) NCT07465263Phase 31 site📍 Beijing CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Tests: SYH2053 Injection, Placebo Injection National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry NCT06546137n/a27 sites📍 Rio Branco📍 Maceió📍 Macapá Hospital do Coracao · Tests: whole genome sequencing Atlantic Lipid Lowering Treatment Optimization Program NCT06439654NA2 sites📍 Clark📍 Springfield Atlantic Health System · Tests: Supportive care A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias NCT07491172Phase 117 sites📍 Hialeah📍 Jacksonville📍 Orlando CRISPR Therapeutics AG · Tests: CTX310 High Intensity Interval Training in the Treatment of Familial Hypercholesterolemia (UPPA-FH) NCT06833944NA1 site📍 Granada Fundación Pública Andaluza para la Investigación Biomédica … · Tests: HIIT intervention program, MICT intervention program A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease NCT06164730Phase 127 sites📍 Dothan📍 Pomona📍 Boca Raton Verve Therapeutics, Inc. · Tests: VERVE-102 Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada NCT02009345n/a1 site📍 Montreal McGill University Health Centre/Research Institute of the M… Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia NCT06634160n/a3 sites📍 Angers📍 Nantes📍 Rennes Nantes University Hospital · Tests: Fibroscan, Sample collection Screening for Familial Hypercholesterolemia in Children NCT06555120NA1 site📍 Amiens Centre Hospitalier Universitaire, Amiens · Tests: blood sample Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies NCT05682378Phase 352 sites📍 Boca Raton📍 New York📍 Cincinnati Novartis Pharmaceuticals · Tests: Inclisiran A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia NCT07421297Phase 32 sites📍 Beijing📍 Beijing CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Tests: SYH2053 injection, SYH2053 injection placebo A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) NCT07058077Phase 2, Phase 347 sites📍 Wilmington📍 Washington D.C.📍 Boca Raton Merck Sharp & Dohme LLC · Tests: Enlicitide Decanoate, Placebo Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH) NCT06458010EARLY Phase 11 site📍 Shanghai RenJi Hospital · Tests: YOLT-101 "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)" NCT07427472NA3 sites📍 Paris📍 Paris📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Coronary computed tomography angiography Cardiovascular Risk in Children With Chronic Conditions Study NCT07086989n/a3 sites📍 Budapest📍 Budapest📍 Budapest Semmelweis University Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis NCT06535542NA1 site📍 Abu Dhabi Abu Dhabi Health Services Company · Tests: Whole Genome Sequencing Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days NCT07614958Phase 31 site📍 Stockton-on-Tees A. Menarini International Licensing S.A. · Tests: Obicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib Russian Familial Hypercholesterolemia Registry NCT02208869n/a5 sites📍 Chelyabinsk📍 Moscow📍 Novosibirsk Russian Cardiology Research and Production Center A Dose-exploration Study of EDP167 in HoFH NCT07489209Phase 21 site📍 Beijing Eddingpharm (Zhuhai) Co., Ltd. · Tests: EDP167 The Spanish Familial Hypercholesterolaemia Cohort Study NCT02693548n/a1 site📍 Madrid Fundación Hipercolesterolemia Familiar A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab NCT07543731n/a1 site📍 Basel Novartis Pharmaceuticals
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy